Lean MASLD: Why Exercise Matters More Than Weight Loss: Gastroenterology | March 2026

Introduction – MASLD in Normal-Weight Individuals

Metabolically dysregulated steatotic liver disease (MASLD) is commonly linked with obesity and metabolic syndrome. However, a significant subset of patients develop MASLD despite having a normal body mass index (BMI)—often referred to as lean or normal-weight MASLD. These individuals may still have metabolic abnormalities such as insulin resistance, visceral adiposity, or sedentary lifestyles. Current global MASLD guidelines recommend 3–5% weight reduction even in normal-weight individuals to reduce liver fat. However, emerging evidence suggests that focusing primarily on weight loss in this population may be misguided and clinically impractical.

Why Weight Reduction May Not Help in Lean MASLD

For patients already within a healthy weight range, further weight loss may provide limited metabolic benefit and can be difficult to achieve or sustain. More importantly, exercise exerts powerful liver-specific metabolic effects independent of body weight changes. Physical activity improves insulin sensitivity, enhances mitochondrial function, and increases hepatic fatty acid oxidation—mechanisms that directly reduce liver fat without requiring weight loss. Clinical studies show that structured aerobic or resistance exercise can reduce intrahepatic fat by 10–30%, even when body weight remains unchanged. Meta-analyses confirm that ≥150 minutes of moderate exercise weekly significantly improves hepatic steatosis independent of weight reduction.

These findings suggest that in lean MASLD, lifestyle interventions should prioritise regular physical activity rather than weight-centric goals, reframing exercise as a direct therapeutic strategy rather than merely a tool for weight loss.